Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 3:23 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 6,600 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Chronic Total Occlusion of Coronary Artery
Interventions: NovaCross; Device
Lead sponsor: Nitiloop Ltd.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 4
States / cities: Little Rock, Arkansas • Naperville, Illinois • New York, New York + 1 more

Conditions: COPD
Interventions: myAirvo3, Pulse oximeter; Device
Lead sponsor: Temple University; Other
Eligibility: 30 Years and older
Enrollment: 642 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 25
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Jacksonville, Florida + 20 more

Conditions: Coronary Artery Disease
Interventions: Placebo Arm, Thienopyridine Therapy, Surveillance Arm; Drug · Device
Lead sponsor: Medtronic Vascular; Industry
Eligibility: 19 Years and older
Enrollment: 2,272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Anderson, South Carolina

Conditions: Respiratory Depression
Interventions: Not listed
Lead sponsor: Medtronic - MITG; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Hypertension, Left Ventricular Hypertrophy, Overweight
Interventions: Aliskiren 150/300 mg, Losartan 50/100 mg, Aliskiren placebo, Losartan 50/100 mg placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Ischemic Stroke
Interventions: Glyburide for Injection; Drug
Lead sponsor: Remedy Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 4
States / cities: Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 1 more

Conditions: Glioblastoma Multiforme, Anaplastic Astrocytoma, Oligoastrocytoma, Mixed, Gliosarcoma
Interventions: Interferon-beta; Genetic
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 5
States / cities: Birmingham, Alabama • Tucson, Arizona • Denver, Colorado + 2 more

Conditions: Bunionectomy, Pain, Postoperative Pain, Acute Pain
Interventions: CG5503 IR, Morphine, Placebo; Drug
Lead sponsor: Grünenthal GmbH; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 291 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 6
States / cities: Pasadena, Maryland • Austin, Texas • Houston, Texas + 3 more

Conditions: Migraine
Interventions: Ubrogepant, Erenumab, Galcanezumab; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 2
States / cities: Springfield, Missouri • West Bend, Wisconsin

Conditions: Chronic Cluster Headache
Interventions: Eptinezumab; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 5
States / cities: Stamford, Connecticut • Ann Arbor, Michigan • Amherst, New York + 2 more

Conditions: Diabetic Macular Edema
Interventions: Triamcinolone Acetonide, Semi-automated Suprachoroidal Microcatheter; Drug · Device
Lead sponsor: Oxular Limited; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 6
States / cities: Bakersfield, California • Minneapolis, Minnesota • Austin, Texas + 2 more

Conditions: Head and Neck Cancer
Interventions: ABBV-181, ABBV-368, ABBV-927; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 3
States / cities: Boston, Massachusetts • Ann Arbor, Michigan • Houston, Texas

Conditions: Obstructive Sleep Apnea of Adult
Interventions: ANNE Sleep; Device
Lead sponsor: Northwestern University; Other
Eligibility: 22 Years and older
Enrollment: 287 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 4
States / cities: Chicago, Illinois • Lake Forest, Illinois • Urbana, Illinois + 1 more

Conditions: Malignant Melanoma, Squamous Cell Carcinoma of Skin
Interventions: THOR-707, Cemiplimab; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Beverly Hills, California

Conditions: Benign Prostatic Hyperplasia
Interventions: Urocross implant, Sham-control; Device · Diagnostic Test
Lead sponsor: Prodeon Medical, Inc; Industry
Eligibility: 45 Years and older · Male only
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 2
States / cities: Maywood, Illinois • Roanoke, Virginia

Conditions: Ischemic Stroke
Interventions: Low Dose Argatroban, High Dose Argatroban, rt-PA (alteplase); Drug
Lead sponsor: Andrew D. Barreto, MD; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Influenza, Human
Interventions: zanamivir aqueous solution; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Months and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 40
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 33 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin degludec, Insulin glargine; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 498 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 34
States / cities: Chandler, Arizona • Tucson, Arizona • Fresno, California + 28 more

Conditions: Chronic Obstructive Pulmonary Disorder
Interventions: BFF MDI 320/9.6 μg, BFF MDI 160/9.6 μg, FF MDI 9.6 μg, BD MDI 320 μg, Symbicort® TBH 400/12 μg BID; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 2,389 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 83
States / cities: Athens, Alabama • Birmingham, Alabama • Dothan, Alabama + 70 more

Conditions: Methylmalonic Acidemia (MMA)
Interventions: Not listed
Lead sponsor: Genespire Srl; Industry
Eligibility: Up to 16 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania

Conditions: Acute Myocardial Infarction
Interventions: CSL112, Placebo; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 1,267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 48
States / cities: Birmingham, Alabama • Huntsville, Alabama • Concord, California + 43 more

Conditions: Narcolepsy, Cataplexy, Excessive Daytime Sleepiness
Interventions: AXS-12 (reboxetine), Placebo; Drug
Lead sponsor: Axsome Therapeutics, Inc.; Industry
Eligibility: 15 Years to 75 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 47
States / cities: Alabaster, Alabama • Peoria, Arizona • Phoenix, Arizona + 43 more

Conditions: Behcet Syndrome
Interventions: Apremilast (CC-10004), Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 4
States / cities: Jacksonville, Florida • Boston, Massachusetts • New York, New York + 1 more

Conditions: B-precursor Acute Lymphoblastic Leukemia
Interventions: Blinatumomab, Current Wearable Heatlth Monitoring System (CWHMS); Drug · Device
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 12
States / cities: Duarte, California • Los Angeles, California • Orange, California + 9 more

Search by objective public record fields.

A Prospective, Multi-Center, Pivotal Study to Evaluate the Safety and Effectiveness of the NovaCross™ Micro-catheter in Facilitating Crossing Chronic Total Occlusion (CTO) Coronary Lesions

myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home

EDUCATE: The MEDTRONIC Endeavor Drug Eluting Stenting: Understanding Care, Antiplatelet Agents and Thrombotic Events

Clinical Utility of Capnography in the PACU( Post-anaesthesia Care Unit)

Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension

Glyburide Advantage in Malignant Edema and Stroke Pilot

Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas

A Trial to Evaluate CG5503 Efficacy and Safety in Acute Pain After Bunionectomy

Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine

A 1-year Trial to Inform About Long-term Exposure to Eptinezumab in Participants With Chronic Cluster Headache (cCH)

Oxulumis® Suprachoroidal Microcatherization of Triesence® in Diabetic Macular Edema

A Study to Assess the Effects of Multiple Study Drug Regimens in Subjects With Newly Diagnosed Locally Advanced Head and Neck Squamous Cell Carcinoma

Comparative Study of the ANNE™ One System to Diagnose Obstructive Sleep Apnea

A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)

Expander-2 Trial: Randomized Study to Evaluate Safety & Efficacy of the Urocross® Expander System & Retrieval Sheath

Randomized Controlled Trial of Argatroban With Tissue Plasminogen Activator (tPA) for Acute Stroke

Safety Study to Assess IV Zanamivir for Treatment of Influenza Infection in Patients Who Are in Hospital

A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO Study

Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD

A Prospective Study of Pediatric Participants up to 16 Years of Age With Methylmalonic Acidemia (MMA) Due to Mutations in the MMUT Gene

A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.

A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy

A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease

Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)